ASX:CSLBiotechs
Assessing CSL’s Valuation After US Tariff Reassurances And Manufacturing Expansion Plans
Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. This has eased immediate revenue and margin concerns.
See our latest analysis for CSL.
Despite the reassurance on US tariffs, CSL’s recent share price return shows mixed momentum, with a 1-day gain of 1.33% at A$142.18, a 90-day share price return of 18.50%, and a 1-year total shareholder return...